Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887976 · ClinicalTrials.gov registry record · Phase 3
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
A Phase 3 study of Prostate Cancer, sponsored by GU Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
- 3
- Study locations
NCT02887976: Completed Phase 3 study of Prostate Cancer, sponsored by GU Research Network.
NCT02887976 is a Phase 3 study of Prostate Cancer that has completed, run by GU Research Network. The registered enrollment target is 2 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887976, a Phase 3 study of Prostate Cancer, has completed, sponsored by GU Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
- 3
- Study locations
Study Summary
An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.
Primary Outcome
Safety as determined by adverse events deemed related to experimental treatment.
Conditions Studied
Interventions
- DRUG Methylprednisolone
- DRUG SoluMatrix™ Abiraterone Acetate
Study Locations (3)
Nebraska
- GU Research Network/Urology PC - Lincoln
- GU Research Network/Urology Cancer Center - Omaha
Kansas
- GU Research Network/Wichita Urology Group - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 3 |
What the finished NCT02887976 record still lists
NCT02887976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Methylprednisolone is the first listed.
NCT02887976 reports a single indexed study location in Nebraska, Kansas.
Frequently Asked Questions
What is clinical trial NCT02887976 about?
NCT02887976 is a clinical study titled "Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201". An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.
What is the current status of trial NCT02887976?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2016-09. Estimated completion is 2017-10-06.
What conditions does trial NCT02887976 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02887976?
The interventions under investigation include: Methylprednisolone (DRUG), SoluMatrix™ Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT02887976?
This trial is sponsored by GU Research Network, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02887976 being conducted?
This trial has 3 study locations across Kansas, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02887976's enrollment target sits among peer trials
2 735th of 735 higher than 1 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia